| 徐丽霞,常 娟,秦纪平,李 蓉,朱 淳.厄贝沙坦对早期糖尿病肾病患者血清hs-CRP、TNF-α、ET及Hcy水平的影响[J].,2019,19(5):907-910 |
| 厄贝沙坦对早期糖尿病肾病患者血清hs-CRP、TNF-α、ET及Hcy水平的影响 |
| Effect of Irbesartan on the Serum hs-CRP, TNF-α, ET and Hcy Levels of Patients with Early Diabetic Nephropathy |
| 投稿时间：2018-06-24 修订日期：2018-07-21 |
| DOI：10.13241/j.cnki.pmb.2019.05.025 |
| 中文关键词: 早期糖尿病肾病 厄贝沙坦 炎症因子 内皮素 同型半胱氨酸 |
| 英文关键词: Early diabetic nephropathy Irbesartan Inflammatory factors Endothelin Homocysteine |
| 基金项目: |
|
| 摘要点击次数: 786 |
| 全文下载次数: 320 |
| 中文摘要: |
| 摘要 目的：探讨厄贝沙坦治疗对早期糖尿病肾病患者血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、内皮素(ET)及同型半胱氨酸(Hcy)水平的影响。方法：入选符合纳入标准的早期糖尿病肾病患者82例，按照随机抽签的方法分为对照组和观察组，每组各41例。对照组在指导患者饮食、合理运动的基础上给予降糖、降压治疗、改善贫血、保证酸碱平衡等，观察组在对照组基础上联合厄贝沙坦治疗。检测两组患者治疗前后血脂指标：甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)；肾功能各项指标：尿素氮(BUN)、血肌酐(SCr)、胱抑素-C(CysC)、24 h尿蛋白定量(24 h UP)以及血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、内皮素(ET)及同型半胱氨酸(Hcy)水平的变化。结果：治疗前，两组血脂指标、肾功能指标、血清hs-CRP、TNF-α、ET及Hcy水平比较差异无统计学意义(P＞0.05)。与治疗前相比，两组患者治疗后血清TC、TG、LDL-C、BUN、SCr、CysC、24h UP、hs-CRP、TNF-α、ET及Hcy水平均显著降低，且观察组以上指标均明显低于对照组(P＜0.05)；而两组血清HDL-C均明显升高，且观察组显著高于对照组(P＜0.05)。结论：厄贝沙坦用于治疗早期糖尿病肾病可更有效改善患者血脂水平、降低血清hs-CRP、TNF-α、ET及Hcy水平，进而保护患者肾功能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Irbesartan on serum high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), endothelin (ET) and homocysteine (Hcy) levels of patients with early diabetic nephropathy. Methods: 82 cases of pa- tients with early diabetic nephropathy were selected and divided into the control group and the observation group according to the ran- dom sampling method, with 41 cases in each group. Patients in the control group were treated with hypoglycemic therapy, antihyperten- sive treatment, anemia improvement and acid-base balance based on the guidance of diet and reasonable exercise. Patients in the observa- tion group were treated with irbesartan on the basis of control group. The blood lipid index: three triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C); the indexes of renal function: urea ni- trogen (BUN), serum creatinine (SCr), Cystatin-C (CysC), 24 h urinary protein (24h UP) and serum levels of hs-CRP, TNF-α, ET and Hcy were detected in patients of two groups before and after treatment. Results: Before treatment, there was no significant difference in the blood lipid index, renal function index, serum hs-CRP, TNF-α, ET and Hcy levels between the two groups(P>0.05). Compared with those before treatment, the levels of serum TC, TG, LDL-C, BUN, SCr, CysC, 24h UP, hs-CRP, TNF-α, ET levels in both groups were all decreased after treatment, while the levels of HDL-C were increased in both groups (P<0.05). The serum TC, TG, LDL-C, BUN, SCr, CysC, 24h UP, hs-CRP, TNF-α, ET levels were lower in the observation group than those of the control group(P<0.05), while the serum level of HDL-C was higher in the observation group than that of the control group(P<0.05). Conclusion: Irbesartan can more effectively improve the level of blood lipids, reduce the serum levels of hs-CRP, TNF-α, ET and Hcy levels and improve the renal function in the treatment of early DN. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
